A recent study published in the journal Clinical Cancer Research has found that a certain protein called KIM-1 may be able to predict renal cell carcinoma up to five years before…
According to a story from Science Daily, researchers have discovered a mechanism that drives the development of renal cell carcinoma. This mechanism could lead to new therapeutic approaches that take…
According to a story from currentargus.com, the annual meeting of the American Society for Clinical Oncology, which takes place in Chicago, is the largest convergence dedicated to cancer research in…
The phase 3 trial of the drug Inlyta for the treatment of patients with a high risk of recurrent renal cell carcinoma (kidney cancer) following nephrectomy (removal of a kidney)…
According to an article from Righting Injustice, a recent study suggests that TNF inhibitors may increase the risk of rare cancers in pediatric patients. The study recommends that children that…
Michael Mullan was only a baby when he was diagnosed with cancer for the first time-- specifically neuroblastoma, a childhood cancer which had a low survival rate. Since then, he…
According to an article from PRNewswire, the drug MVASI (biosimilar bevacizumab) was just granted marketing authorization by the European Commission. Developed by Amgen and Allergan, this treatment has been approved…
According to an article at publicnow.com, the FDA has granted Breakthrough Therapy Designation to avelumab combined with INLYTA (axitinib) for people with advanced renal cell carcinoma. This designation should accelerate…
The more scientists learn about gut bacteria, the more fascinating it becomes. It can affect your mood, the foods you crave, and according two new studies, it can even change…
It was a classic story of boy-on-dialysis-waiting-for-a-kidney-transplant meets girl. The year was 1997. Larry Wetsch's kidneys were in dire state, hardening due to a rare disease called glomerulonephritis. Glomerulonephritis happens when…
Day two of Global Gene's 2017 Patient Advocacy Summit started out with a fire side chat with Christopher Austin, MD, the Director of the NIH's National Center for Advancing Translational…
In April of this year, Argos Therapeutics reported interim results from its Phase 3 ADAPT clinical trial of rocapuldencel-T in combination with the normal standard-of-care for the treatment of newly…
Xynomic Pharma, a United States-based oncology research and development company, announced at the end of last month that it had entered into a partnership with the University of California San…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
